PKTX - ProtoKinetix, Incorporated

Other OTC - Other OTC Delayed Price. Currency in USD
+0.0050 (+7.14%)
At close: 9:46AM EST
Stock chart is not supported by your current browser
Previous Close0.0700
Bid0.000 x 0
Ask0.000 x 0
Day's Range0.0750 - 0.0780
52 Week Range0.0300 - 0.1300
Avg. Volume42,070
Market Cap19.346M
Beta (3Y Monthly)3.16
PE Ratio (TTM)N/A
EPS (TTM)-0.006
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Business Wire3 months ago

    ProtoKinetix Begins Cardiovascular Research

    ProtoKinetix, Incorporated ( (the "Company" or "ProtoKinetix") (OTCQB:PKTX) Is pleased to announce the launch of a proof of concept study in the field of cardiovascular sciences. Dr. Thomas Pulinilkunnil, Associate Professor, Department of Biochemistry and Molecular Biology, Dalhousie University is the principal investigator on this project. Upon the completion of this phase of testing, pre-clinicalscreening of organ preservation and metabolic effects of PKX-001 will be undertaken in transplant ready cardiac tissue.

  • Business Wire4 months ago

    ProtoKinetix Enters into 3rd Phase of Retinal Cell Replacement Therapy Testing at UBC

    ProtoKinetix, Incorporated ( (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) has entered into the 3rd phase of testing in retinal cell replacement therapy at the University of British Columbia. Due to the positive results from the first two phases of testing where the AAGP® treated cells showed a dramatic increase in survivability versus untreated cells over a four-week period, we are now expanding the study. The new study shall include two animal models over a longer period of time to test whether the AAGP® treated cells continue to develop into retinal cells to potentially restore vision in humans.

  • Business Wire6 months ago

    ProtoKinetix’s AAGP® Signs a Material Transfer Agreement with a Reputed International Biotech Company

    ProtoKinetix, Incorporated ( (the "Company" or "ProtoKinetix") (OTCQB:PKTX) is pleased to announce that it has executed a Material Transfer Agreement (MTA) with a reputed biotechnology company having a number of worldwide offices on four continents. Before testing a drug in human patients, researchers use primary cells from different human donors to verify that the same effects are observed.

  • Business Wire11 months ago

    ProtoKinetix Has Entered into a Research Agreement with The University of British Columbia to Test the Effect of its AAGP™ on Monoclonal Antibody Production and Bone Marrow Recovery

    ProtoKinetix, Incorporated is pleased to announce that it has entered into a research agreement with The University of British Columbia , under the direction of principal investigator Dr.